Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Honeywell’s Technology To Capture Carbon At Exxon’s Texas Facility – $HON $XOM $DIA $ATOS

By John F. Heerdink, Jr.

As per reports, Exxon Mobil Corp (XOM) uses technology from Honeywell International Inc. (HON) to capture carbon dioxide at a proposed hydrogen production facility in Texas. Honeywell’s technology would enable Exxon to capture about 7 million tons of carbon dioxide per year, equivalent to emissions from 1.5 million automobiles for one year. The facility at Baytown, Texas, facility, is expected to start operating by 2028. However, the terms of the agreement were not disclosed.

 The Baytown hydrogen plant is part of Exxon’s plan to make money from helping other companies decarbonize operations, and is expected to produce 1 billion cubic feet of hydrogen in a day.

Our ready-now carbon capture technology works to decarbonize production processes and is effective because it can allow for significant emissions reduction that can play a major role in the energy transition,” stated Barry Glickman, a Honeywell vice president.

Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.


Atossa Therapeutics

Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet need in cancer, today (Feb. 13, 2023) announced that the United States Patent and Trademark Office (USPTO) has granted a new patent (No. 11,572,334) directed to (Z)-endoxifen encapsulated in an enteric capsule. Enteric capsules have an acid resistant coating to prevent them from dissolving when they pass through the stomach. Enteric capsules are dissolved when they pass through an alkaline environment, which is usually when they reach the small intestine. Delivering oral (Z)-endoxifen via an enteric capsule prevents breakdown of the endoxifen in the stomach. A short ‘explainer’ video about the new patent can be found here: Patent Update – Video Explainer. 

This patent further reinforces Atossa’s broad Intellectual Property portfolio related to (Z)-endoxifen. Atossa is developing its proprietary (Z)-endoxifen in both the breast cancer treatment and prevention settings. Phase 2 trials are ongoing with the goal of changing the treatment paradigm for patients who are not benefiting from currently approved drugs and helping reduce the incidence of breast cancer.

Learn more by clicking here. 

(Read Original Story: Exxon to use Honeywell carbon capture tech at hydrogen facility in Reuters)


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us